Decreased MicroRNA-22 is Associated with Poor Prognosis in Cervical Cancer

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2020 Jan 23

PMID 31966827

Citations 2

Authors

Lu Zhang

Bin Chen

Ding Ding

Affiliations

Soon will be listed here.

Abstract

Cervical cancer is one of the most lethal gynecological malignancy. Aberrant expression of microRNAs (miRNAs) is associated with carcinogenesis of cervical cancer. The aim of current study was to elucidate the clinical significance of miR-22 in patients with cervical cancer. The expression levels of miR-22 in cervical intraepithelial neoplasia (CIN) and cervical cancer tissues as well as cervical cancer cell lines were quantified using real-time PCR. Then the potential prognostic value of the miR-22 was assessed. Our results showed that the expression level of miR-22 was significantly lower in cervical cancer tissues and cell lines. miR-22 levels were inversely correlated clinical stage both in CIN and cervical cancer. In addition, low expression of miR-22 was significantly associated with larger tumor size, presence of lymph node metastasis, and advanced tumor stage. Moreover, the patients expressing low levels of miR-22 had poorer five year overall survival and disease free survival. Multivariate analysis identified miR-22 as an independent prognostic factor for cervical cancer patients' overall survival. Taken together, we demonstrate that the miR-22 may serve as a novel therapeutic target and prognostic marker in patients with cervical cancer.

Citing Articles

The therapeutic potential of exosomal miR-22 for cervical cancer radiotherapy.

Konishi H, Hayashi M, Taniguchi K, Nakamura M, Kuranaga Y, Ito Y Cancer Biol Ther. 2020; 21(12):1128-1135.

PMID: 33190594 PMC: 7722788. DOI: 10.1080/15384047.2020.1838031.

MicroRNA-22 enhances radiosensitivity in cervical cancer cell lines via direct inhibition of c-Myc binding protein, and the subsequent reduction in hTERT expression.

Nakamura M, Hayashi M, Konishi H, Nunode M, Ashihara K, Sasaki H Oncol Lett. 2020; 19(3):2213-2222.

PMID: 32194719 PMC: 7038919. DOI: 10.3892/ol.2020.11344.

References

DAngelo B, Benedetti E, Cimini A, Giordano A . MicroRNAs: A Puzzling Tool in Cancer Diagnostics and Therapy. Anticancer Res. 2016; 36(11):5571-5575. DOI: 10.21873/anticanres.11142. View

Jiang R, Deng L, Zhao L, Li X, Zhang F, Xia Y . miR-22 promotes HBV-related hepatocellular carcinoma development in males. Clin Cancer Res. 2011; 17(17):5593-603. DOI: 10.1158/1078-0432.CCR-10-1734. View

Zhang B, Farwell M . microRNAs: a new emerging class of players for disease diagnostics and gene therapy. J Cell Mol Med. 2007; 12(1):3-21. PMC: 3823469. DOI: 10.1111/j.1582-4934.2007.00196.x. View

Xin M, Qiao Z, Li J, Liu J, Song S, Zhao X . miR-22 inhibits tumor growth and metastasis by targeting ATP citrate lyase: evidence in osteosarcoma, prostate cancer, cervical cancer and lung cancer. Oncotarget. 2016; 7(28):44252-44265. PMC: 5190093. DOI: 10.18632/oncotarget.10020. View

Sankaranarayanan R, Ferlay J . Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 2005; 20(2):207-25. DOI: 10.1016/j.bpobgyn.2005.10.007. View

Wang F, Li B, Xie X . The roles and clinical significance of microRNAs in cervical cancer. Histol Histopathol. 2015; 31(2):131-9. DOI: 10:14670/HH-11-666. View

Sun L, Jiang R, Li J, Wang B, Ma C, Lv Y . MicoRNA-425-5p is a potential prognostic biomarker for cervical cancer. Ann Clin Biochem. 2016; 54(1):127-133. DOI: 10.1177/0004563216649377. View

Ling B, Wang G, Long G, Qiu J, Hu Z . Tumor suppressor miR-22 suppresses lung cancer cell progression through post-transcriptional regulation of ErbB3. J Cancer Res Clin Oncol. 2012; 138(8):1355-61. DOI: 10.1007/s00432-012-1194-2. View

Adegoke O, Kulasingam S, Virnig B . Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Health (Larchmt). 2012; 21(10):1031-7. PMC: 3521146. DOI: 10.1089/jwh.2011.3385. View

10.

Sakuragi N . Refining insight into cervical cancer progression. Lancet Oncol. 2014; 15(4):371-2. DOI: 10.1016/S1470-2045(14)70085-3. View

11.

Song S, Pandolfi P . miR-22 in tumorigenesis. Cell Cycle. 2013; 13(1):11-2. PMC: 3925720. DOI: 10.4161/cc.27027. View

12.

Yamakuchi M, Yagi S, Ito T, Lowenstein C . MicroRNA-22 regulates hypoxia signaling in colon cancer cells. PLoS One. 2011; 6(5):e20291. PMC: 3100326. DOI: 10.1371/journal.pone.0020291. View

13.

Wahid F, Shehzad A, Khan T, Kim Y . MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta. 2010; 1803(11):1231-43. DOI: 10.1016/j.bbamcr.2010.06.013. View

14.

Song S, Ito K, Ala U, Kats L, Webster K, Sun S . The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell. 2013; 13(1):87-101. PMC: 3767186. DOI: 10.1016/j.stem.2013.06.003. View

15.

Jiang X, Hu C, Arnovitz S, Bugno J, Yu M, Zuo Z . miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia. Nat Commun. 2016; 7:11452. PMC: 5477496. DOI: 10.1038/ncomms11452. View

16.

Zhou J, Zheng S, Liu J, Shi R, Yu H, Wei M . MiR-519d facilitates the progression and metastasis of cervical cancer through direct targeting Smad7. Cancer Cell Int. 2016; 16:21. PMC: 4802873. DOI: 10.1186/s12935-016-0298-1. View

17.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

18.

Zuo Q, Cao L, Yu T, Gong L, Wang L, Zhao Y . MicroRNA-22 inhibits tumor growth and metastasis in gastric cancer by directly targeting MMP14 and Snail. Cell Death Dis. 2015; 6:e2000. PMC: 4670920. DOI: 10.1038/cddis.2015.297. View

19.

Kong J, Di C, Piao J, Sun J, Han L, Chen L . Ezrin contributes to cervical cancer progression through induction of epithelial-mesenchymal transition. Oncotarget. 2016; 7(15):19631-42. PMC: 4991407. DOI: 10.18632/oncotarget.7779. View